Disclosure of microbicide gel use to sexual partners: Influence on adherence in the CAPRISA 004 trial

AIDS and Behavior

Volumn 18, Issue 5, 2014, Pages 849-854

  Mngadi, Kathryn Therese ^a   Maarschalk, Silvia ^a   Grobler, Anneke C ^a   Mansoor, Leila E ^a   Frohlich, Janet A ^a   Madlala, Bernadette ^a   Ngcobo, Nelisiwe ^a   Abdool Karim, Salim S ^a,b   Abdool Karim, Quarraisha ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Mailman School of Public Health   (United States)

Author keywords

Adherence; HIV prevention; Microbicides; Partner disclosure; Pre exposure prophylaxis

Indexed keywords

ADENINE; ANTIINFECTIVE AGENT; GEL; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; CONDOM; FEMALE; GEL; HIV INFECTIONS; HUMAN; INTERPERSONAL COMMUNICATION; INTERVIEW; MEDICATION COMPLIANCE; PSYCHOLOGY; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUALITY; SOCIOECONOMICS; SOUTH AFRICA; UTILIZATION; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS; CONDOMS; DISCLOSURE; FEMALE; GELS; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; QUESTIONNAIRES; SEXUAL BEHAVIOR; SEXUAL PARTNERS; SOCIOECONOMIC FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84899637751     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-014-0696-0     Document Type: Article

References (17)

1. UNAIDS. World AIDS Day Report. 2012. www.un.org/en/events/aidsday/2012/ report.shtm. Accessed 13 March 2013.
2. Stein ZA. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80(4):460-2.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, LE Mansoor, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
4. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378(9787):279-81.
5. Stirratt M, Gordon C. Adherence to biomedical HIV prevention methods: considerations drawn from HIV treatment adherence research. Curr HIV/AIDS Rep. 2008;5(4):186-92.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
7. Kharsany AB, Karim QA, Karim SS. Uptake of provider-initiated HIV testing and counseling among women attending an urban sexually transmitted disease clinic in South Africa: missed opportunities for early diagnosis of HIV infection. AIDS Care. 2010;22(5):533-7.
8. Kharsany AB, Hancock N, Frohlich JA, Humphries HR, Abdool Karim SS, Abdool Karim Q. Screening for 'window-period' acute HIV infection among pregnant women in rural South Africa. HIV Med. 2010;11(10):661-5.
9. Carballo-Dieguez A, Balan IC, Morrow K, Rosen R, Mantell JE, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050). AIDS Care. 2007;19(8):1026-31.
10. Greene E, Batona G, Hallad J, Johnson S, Neema S, Tolley EE. Acceptability and adherence of a candidate microbicide gel among high-risk women in Africa and India. Cult Health Sex. 2010;12(7):739-54.
11. Montgomery ET, Cheng H, van der Straten A, Chidanyika AC, Lince N, Blanchard K, et al. Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa. AIDS Behav. 2010;14(3):629-38.
12. Montgomery ET, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2011;15(5):959-69.
13. van der Straten A, Kang MS, Posner SF, Kamba M, Chipato T, Padian NS. Predictors of diaphragm use as a potential sexually transmitted disease/HIV prevention method in Zimbabwe. Sex Transm Dis. 2005;32(1):64-71.
14. Microbicide Trials Network. Daily HIV prevention approaches didn't work for Arican women in the voice study [press release], Atlanta, March 4 2013.
15. Berger RE. Re: preexposure chemoprophylaxis for HIV prevention in men who have sex with men. J Urol. 2011;185(5):1729-30.
16. Montgomery CM, Gafos M, Lees S, Morar NS, Mweemba O, Ssali A, et al. Re-framing microbicide acceptability: findings from the MDP301 trial. Cult Health Sex. 2010;12(6):649-62.
17. Turner AN, De Kock AE, Meehan-Ritter A, Blanchard K, Sebola MH, Hoosen AA, et al. Many vaginal microbicide trial participants acknowledged they had misreported sensitive sexual behavior in face-to-face interviews. J Clin Epidemiol. 2009;62(7):759-65.